Xinzhao Wang
Current Organizations / Institutes
The organizations/institutes from the scholar's latest article
Previous Organizations / Institutes
The organizations / institutes from the scholar's other articles in the past ten years
Research Subjects
Xinzhao Wang has a total of 36 co-authors. Here are the top co-authors by number of shared publications:
- Zhiyong Yu
Shandong First Medical University Affiliated Tumor Hospital, Jinan, China
27 shared publications - Bernard Mark Evers
University of Kentucky
24 shared publications - Bo Dong
Department of Pharmacology & Nutritional Sciences, University of Kentucky School of Medicine, Lexington, Kentucky
24 shared publications - Jianlin Wang
Department of Toxicology and Cancer Biology, University of Kentucky
24 shared publications - Jiong Deng
Medical Research Center, Affiliated Hospital of Binzhou Medical University, Binzhou, China
24 shared publications - Tao Dai
Department of Pharmacology & Nutritional Sciences, University of Kentucky School of Medicine, Lexington, Kentucky
24 shared publications
Latest Publications
- Open Access
- 1 January 2026
- Published by Taylor & Francis in Breast Cancer: Targets and Therapy
- Vol. ume 18, 1-14
Receptor Discordance and Molecular Subtype Changes in Visceral Metastases of Breast Cancer
Background: Visceral metastases in breast cancer demonstrate considerable molecular heterogeneity. This study examines changes in receptor status and molecular subtypes between primary breast cancer and visceral metastases. Methods: A retrospective analysis was conducted on 430 patients diagnosed with breast cancer and visceral metastases, including 138 with lung metastases and 292 with liver metastases. Receptor statuses (estrogen receptor [ER], progesterone receptor [PR], human epidermal growth factor receptor 2 [HER2]) were assessed in both primary and metastatic tumors. Discordance in molecular subtypes was assessed, and factors influencing receptor changes were identified. Survival outcomes were estimated using Kaplan–Meier analysis. Results: Receptor discordance was observed in 47.9% (206/430) of patients, with a higher frequency in liver metastases (51.0%) than in lung metastases (41.3%). PR discordance was the most frequent (36.2%), followed by ER (18.9%) and HER2 (7.2%). Molecular subtype discordance occurred in 36.1% of patients, with the highest rate in Luminal A tumors (85.7%). Multivariate analysis identified pN3 stage and molecular subtype as independent predictors. Kaplan–Meier survival analysis showed that patients with ER gain had significantly improved disease-free survival (DFS) compared with those with ER loss (75.4 vs 44.5 months, P = 0.0092). Moreover, molecular subtype discordance was associated with longer DFS (63.9 vs 49.1 months, P = 0.0079). Conclusion: This study emphasizes that there are significant differences in receptor expression and molecular subtypes between primary breast tumors and their visceral metastases. The receptor is more likely to change in patients with liver metastasis and Luminal A or Luminal B (HER2+) tumors, highlighting the importance of repeat biopsy in the metastatic environment. These findings can be used to identify high-risk patients and provide them with better treatment plans.
- 1 January 2026
- Published by Taylor & Francis in Breast Cancer: Targets and Therapy
- Vol. ume 18, 1-14
Open AccessReceptor Discordance and Molecular Subtype Changes in Visceral Metastases of Breast Cancer
Background: Visceral metastases in breast cancer demonstrate considerable molecular heterogeneity. This study examines changes in receptor status and molecular subtypes between primary breast cancer and visceral metastases. Methods: A retrospective analysis was conducted on 430 patients diagnosed with breast cancer and visceral metastases, including 138 with lung metastases and 292 with liver metastases. Receptor statuses (estrogen receptor [ER], progesterone receptor [PR], human epidermal growth factor receptor 2 [HER2]) were assessed in both primary and metastatic tumors. Discordance in molecular subtypes was assessed, and factors influencing receptor changes were identified. Survival outcomes were estimated using Kaplan–Meier analysis. Results: Receptor discordance was observed in 47.9% (206/430) of patients, with a higher frequency in liver metastases (51.0%) than in lung metastases (41.3%). PR discordance was the most frequent (36.2%), followed by ER (18.9%) and HER2 (7.2%). Molecular subtype discordance occurred in 36.1% of patients, with the highest rate in Luminal A tumors (85.7%). Multivariate analysis identified pN3 stage and molecular subtype as independent predictors. Kaplan–Meier survival analysis showed that patients with ER gain had significantly improved disease-free survival (DFS) compared with those with ER loss (75.4 vs 44.5 months, P = 0.0092). Moreover, molecular subtype discordance was associated with longer DFS (63.9 vs 49.1 months, P = 0.0079). Conclusion: This study emphasizes that there are significant differences in receptor expression and molecular subtypes between primary breast tumors and their visceral metastases. The receptor is more likely to change in patients with liver metastasis and Luminal A or Luminal B (HER2+) tumors, highlighting the importance of repeat biopsy in the metastatic environment. These findings can be used to identify high-risk patients and provide them with better treatment plans.
- Open Access
- 1 November 2024
- Published by Taylor & Francis in Journal of Inflammation Research
- Vol. ume 17, 8569-8587
Uncovering SPP1+ Macrophage, Neutrophils and Their Related Diagnostic Biomarkers in Intracranial Aneurysm and Subarachnoid Hemorrhage
Background: Intracranial aneurysms (IA) frequently cause subarachnoid hemorrhage (SAH) and have poor prognosis. However, the molecular mechanisms and diagnostic biomarkers associated with IA and ruptured IA (rIA) remain poorly understood. Methods: In this study, single-cell and transcriptome datasets were obtained from the GEO database. The cell populations were annotated to identify potential pathogenic subpopulations, followed by intercellular communication, pseudotime, and SCENIC analyses. Proteome-wide and transcriptome-wide Mendelian randomization (MR) analyses were conducted to identify risk factors for IA and SAH. The major pathological changes and diagnostic biomarkers of IA and SAH were identified based on the transcriptome datasets. A clinical cohort was established to identify the diagnostic biomarkers and validate the results. Results: Macrophages and neutrophils were predominantly increased in IA and rIA tissues, and neutrophils were markedly upregulated in the blood of SAH patients. SPP1+ Macrophage was progressively elevated in aneurysms, promoting vascular smooth muscle cell (VSMC) phenotypic transformation and collagen matrix remodeling through the SPP1 and TGF-β pathways. Furthermore, HIF1α regulon was enriched in SPP1+ Macrophage, mediating inflammation and metabolic reprogramming, which contributed to IA progression. Integrated MR analysis identified CD36 as a risk factor for both IA and SAH, and it has been recognized as an effective blood biomarker for SAH. Neutrophils and their related indicators have emerged as excellent biomarkers of SAH in clinical cohorts. Conclusion: This study highlighted the detrimental role of SPP1+ Macrophage in IA and SAH using single-cell sequencing and MR analyses. CD36 was identified as a risk factor for IA and SAH and was also an efficient blood biomarker for SAH. In a clinical cohort, neutrophils and related indicators were valuable for the early diagnosis of SAH.
- 1 November 2024
- Published by Taylor & Francis in Journal of Inflammation Research
- Vol. ume 17, 8569-8587
Open AccessUncovering SPP1+ Macrophage, Neutrophils and Their Related Diagnostic Biomarkers in Intracranial Aneurysm and Subarachnoid Hemorrhage
Background: Intracranial aneurysms (IA) frequently cause subarachnoid hemorrhage (SAH) and have poor prognosis. However, the molecular mechanisms and diagnostic biomarkers associated with IA and ruptured IA (rIA) remain poorly understood. Methods: In this study, single-cell and transcriptome datasets were obtained from the GEO database. The cell populations were annotated to identify potential pathogenic subpopulations, followed by intercellular communication, pseudotime, and SCENIC analyses. Proteome-wide and transcriptome-wide Mendelian randomization (MR) analyses were conducted to identify risk factors for IA and SAH. The major pathological changes and diagnostic biomarkers of IA and SAH were identified based on the transcriptome datasets. A clinical cohort was established to identify the diagnostic biomarkers and validate the results. Results: Macrophages and neutrophils were predominantly increased in IA and rIA tissues, and neutrophils were markedly upregulated in the blood of SAH patients. SPP1+ Macrophage was progressively elevated in aneurysms, promoting vascular smooth muscle cell (VSMC) phenotypic transformation and collagen matrix remodeling through the SPP1 and TGF-β pathways. Furthermore, HIF1α regulon was enriched in SPP1+ Macrophage, mediating inflammation and metabolic reprogramming, which contributed to IA progression. Integrated MR analysis identified CD36 as a risk factor for both IA and SAH, and it has been recognized as an effective blood biomarker for SAH. Neutrophils and their related indicators have emerged as excellent biomarkers of SAH in clinical cohorts. Conclusion: This study highlighted the detrimental role of SPP1+ Macrophage in IA and SAH using single-cell sequencing and MR analyses. CD36 was identified as a risk factor for IA and SAH and was also an efficient blood biomarker for SAH. In a clinical cohort, neutrophils and related indicators were valuable for the early diagnosis of SAH.
- Open Access
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Table S3 from FBXO24 suppresses breast cancer tumorigenesis by targeting LSD1 for Ubiquitination
Supplemental Table S3. Tumor samples used for analysis
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessTable S3 from FBXO24 suppresses breast cancer tumorigenesis by targeting LSD1 for Ubiquitination
Supplemental Table S3. Tumor samples used for analysis
- Open Access
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Table S1 from FBXO24 suppresses breast cancer tumorigenesis by targeting LSD1 for Ubiquitination
The used antibodies including company, catalog number and dilution.
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessTable S1 from FBXO24 suppresses breast cancer tumorigenesis by targeting LSD1 for Ubiquitination
The used antibodies including company, catalog number and dilution.
- Open Access
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 2 from FBXO24 suppresses breast cancer tumorigenesis by targeting LSD1 for Ubiquitination
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 2 from FBXO24 suppresses breast cancer tumorigenesis by targeting LSD1 for Ubiquitination
- Open Access
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 1 from FBXO24 suppresses breast cancer tumorigenesis by targeting LSD1 for Ubiquitination
FBXO24 regulates LSD1 at protein levels.
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 1 from FBXO24 suppresses breast cancer tumorigenesis by targeting LSD1 for Ubiquitination
FBXO24 regulates LSD1 at protein levels.
- Open Access
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Table S2 from FBXO24 suppresses breast cancer tumorigenesis by targeting LSD1 for Ubiquitination
The sequence of primers for RT-qPCR and ChIP-qPCR.
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessTable S2 from FBXO24 suppresses breast cancer tumorigenesis by targeting LSD1 for Ubiquitination
The sequence of primers for RT-qPCR and ChIP-qPCR.
- Open Access
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Supplemental Figure 4 from FBXO24 suppresses breast cancer tumorigenesis by targeting LSD1 for Ubiquitination
The expression of FBXO24 is inversely associated with the expression of LSD1.
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplemental Figure 4 from FBXO24 suppresses breast cancer tumorigenesis by targeting LSD1 for Ubiquitination
The expression of FBXO24 is inversely associated with the expression of LSD1.
- Open Access
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Supplementary Figure 3 from FBXO24 suppresses breast cancer tumorigenesis by targeting LSD1 for Ubiquitination
FBXO24 blocks tumor migration and invasion.
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessSupplementary Figure 3 from FBXO24 suppresses breast cancer tumorigenesis by targeting LSD1 for Ubiquitination
FBXO24 blocks tumor migration and invasion.
- Open Access
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Table S4 from FBXO24 suppresses breast cancer tumorigenesis by targeting LSD1 for Ubiquitination
Supplemental table 4. Tumor samples with Lymph node metastases of breast cancer.
- 16 September 2024
- Published by American Association for Cancer Research (AACR)
Open AccessTable S4 from FBXO24 suppresses breast cancer tumorigenesis by targeting LSD1 for Ubiquitination
Supplemental table 4. Tumor samples with Lymph node metastases of breast cancer.